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The potential of the skin immune system for the generation of both powerful humoral and cellular immune
responses is now well established. However, the mechanisms responsible for the efficacy of skin antigen-
presenting cells (APCs) during intradermal (ID) vaccination still remain to be elucidated. We have previously
demonstrated in clinical trials that preferential targeting of Langerhans cells (LCs) by transcutaneous
immunization shapes the immune response toward vaccine-specific CD8 T cells. Others have shown that ID
inoculation of a vaccine, which targets dermal APCs, mobilizes both the cellular and humoral arms of immunity.
Here, we investigated the participation of epidermal LCs in response to ID immunization. When human or
mouse skin was injected ID with a particle-based vaccine, we observed significant modifications in the
morphology of epidermal LCs and their mobilization to the dermis. We further established that this LC
recruitment after ID administration was essential for the induction of antigen-specific CD8 T cells, but was,
however, dispensable for the generation of specific CD4 T cells and neutralizing antibodies. Thus, epidermal
and dermal APCs shape the outcome of the immune responses to ID vaccination. Their combined potential
provides new avenues for the development of vaccination strategies against infectious diseases.
Journal of Investigative Dermatology (2012) 132, 615–625; doi:10.1038/jid.2011.346; published online 15 December 2011
INTRODUCTION
Skin has always been a challenging immune target for
vaccine delivery (Romani et al., 2010b). In particular, the
availability of functionally active resident and infiltrating
antigen-presenting cells (APCs) at the site of inoculation is
crucial for the optimal capture and presentation of
vaccine-derived antigens (Sumida et al., 2004). Among skin
vaccine routes, intradermal (ID) delivery has been extensively
tested in many clinical trials (Lambert and Laurent,
2008; Nicolas and Guy, 2008) including vaccination against
rabies (Sabchareon et al., 1998; Charest et al., 2000; Vien
et al., 2008), hepatitis B (Egemen et al., 1998; Henderson
et al., 2000), and influenza (Frech et al., 2005; Belshe,
2007). It appears that the ID route is capable of inducing a
humoral immune response that is equivalent or comparable
to the one induced by the intramuscular or subcutaneous
routes but with a lower dose of antigen, generally a fifth
of the standard dose used for an intramuscular vaccine.
Nevertheless, the cellular mechanisms involved in the
induction of T-cell-mediated immune responses remain to
be studied.
It is now well established that skin APCs can take up
vaccine compounds, process them, and present them to
T and B cells in the draining lymph node (DLN), resulting
in the initiation of cellular and humoral immune responses
(Kupper and Fuhlbrigge, 2004; Mahe et al., 2009). However,
evidence in the literature suggests that epidermal Langerhans
cells (LCs) and dermal dendritic cells (DDCs) exhibit
functional differences in the induction of cellular and
humoral immunity (Romani et al., 2010b; Ueno et al.,
2010a, 2010b). In a recent phase I clinical trial, we have
shown that transcutaneous immunization through open
hair follicles, which allows the targeting of follicular LCs,
preferentially induces CD8 T cells, whereas the intramuscular
route cannot (Vogt et al., 2006, 2008; Combadiere et al.,
2010). Here, we studied the role of epidermis-resident LCs
after the ID injection of particulate vaccine compounds,
and elucidated fundamental mechanisms involved in the
induction of cellular immune responses.
& 2012 The Society for Investigative Dermatology www.jidonline.org 615
ORIGINAL ARTICLE
Received 20 March 2011; revised 21 June 2011; accepted 16 July 2011;
published online 15 December 2011
1Laboratory of Immunity and Infection, Institut National de la Sante´ et de la
Recherche Me´dicale, INSERM UMR-S 945 and Universite´ Pierre et Marie
Curie (UPMC Univ Paris 06), Paris, France; 2Institut de Biologie et Chimie des
Prote´ines, UMR 5086 CNRS/UCBL, Lyon, France and 3Clinical Research
Center for Hair and Skin Science, Department of Dermatology and Allergy,
Charite´-Universita¨tsmedizin Berlin, Berlin, Germany
Correspondence: Be´hazine Combadie`re, Laboratory of Immunity and
Infection, Institut National de la Sante´ et de la Recherche Me´dicale, INSERM
UMR-S 945, 91 Boulevard de l’Hoˆpital, 75013 Paris, France.
E-mail: behazine.combadiere@upmc.fr
Abbreviations: APC, antigen-presenting cell; (D)DC, (dermal) dendritic cell;
DLN, draining lymph node; DT, diphtheria toxin; EGFP, enhanced green
fluorescent protein; ID, intradermal; LC, Langerhans cell; MVA, modified
vaccinia virus Ankara; PLA, poly(lactic) acid
RESULTS
Poly D, L-lactic acid (PLA) or modified vaccinia virus Ankara
(MVA) dermal injection induces morphological modifications
of epidermal LCs and their translocation to the dermis
The behavior of epidermal LCs has been monitored after
dermal inoculation of nanoparticles (6-Coumarin-labeled
PLA, 6-Coumarin PLA), MVA enhanced green fluorescent
protein (EGFP), or phosphate-buffered saline (PBS; Figure 1
and Supplementary Figure S1 online). Quantitative measure-
ments of LC-associated dendrite length (Figure 1a), dendrite
number (Figure 1b), LC density (Figure 1c), LC area (mm2;
Supplementary Figure S1a online), and percentage of LCs in
the epidermis (Supplementary Figure S1b online) have been
recorded after immunostaining of 50 randomly chosen
epidermal fields, using the CD207 marker. Representative
microscopic epidermal fields or typical LCs are shown below
each graph in Figure 1.
We observed a significant decrease in LC dendrite length
(Figure 1a), dendrite number (Figure 1c), and LC area
(Supplementary Figure S1a online) at 2 hours after ID inocula-
tion of PLA (Po0.001) and at 4 hours after ID inoculation of
MVA EGFP (Po0.001) compared with PBS-injected animals.
Independently of the type of compound, all morphological
parameters slowly recovered baseline levels after 16 hours
and remained stable thereafter (Figure 1, Supplementary
Figure S1a online). Simultaneously, the density of LCs and
the percentage of LCs/epidermal sheet were significantly
decreased in epidermal layers 2–3 hours after 6-Coumarin
PLA ID injection and 4 hours after MVA-EGFP (Figure 1c,
Supplementary Figure S1b online), to recover the baseline
level at 16 hours post ID injection. Thus, using multiple
quantitative parameters, we clearly demonstrated that ID
inoculation of either of the two distinct particulate com-
pounds is responsible for major modifications in epidermal
LCs, including changes in their morphology and density
within the epidermis.
Further, we investigated the translocation of LCs from the
epidermis to the dermis. Epidermal or dermal cell suspen-
sions (n¼ 6 mice, three independent experiments) were
prepared 6 hours after MVA ID injection. We used a multi-
parametric flow cytometry analysis to distinguish epidermal
LCs from other DDCs (Merad et al., 2008; Figure 2). In the
epidermis, one could detect epidermal CD11cþCD207þ
CD103 resident LCs; three different cell populations were
identified in the dermis (Figure 2a): (1) CD11cþCD103þ
CD207 cells representing CD103þ DDCs, (2) CD11cþ
CD103þCD207þ cells representing CD207þ DDCs (Gin-
houx et al., 2007), and (3) CD11cþCD103CD207þ cells
defined as transmigrating epidermal LCs (Merad et al., 2008).
We found a 2-fold decrease in the percentage of
CD11cþCD207þCD103 resident LCs in the epidermis
after ID injection of MVA compared with the percentage of
control PBS-injected mice. On the contrary, we found a
2-fold increase in the percentage of LCs present in the
dermis after MVA ID administration compared with PBS
control mice (Figure 2b). The percentage of CD103þ and
CD207þ DDCs, which are essentially resident dermal cells,
was not modified.
We also observed similar results on skin cryosections
6 hours after MVA-EGFP ID injection (MVA but expressing
the green fluorescent protein EGFP). We showed the
presence of numerous LCs (CD207high) in the dermis at the
ID injection site (visualization of MVA-EGFP green fluores-
cence), but not at the PBS injection site (Figure 2c). Together,
these results strongly demonstrate that the dermal delivery
of a particle-based vaccine induces a rapid translocation of
epidermal LCs to the site of antigen delivery (dermis) within a
few hours following the injection.
Epidermal LCs shuttle MVA antigens to the DLNs after ID
inoculation
We then asked whether these transmigrating LCs were
capable of antigen capture before potential homing to the
DLNs. At 6 hours after MVA-EGFP ID injection, dermal cell
suspensions were prepared (n¼5 mice, four independent
experiments). The dermal CD11cþCD103CD207þ trans-
migrating LCs were sorted by flow cytometry and assessed for
MVA-EGFP detection (Figure 2d and e). MVA-EGFP was
detectable in 0.62% of LCs isolated from the dermis,
compared with PBS control mice (Figure 2d and e). In
addition, MVA-EGFP particles were detected in sorted
LCs (Figure 2d). These results clearly demonstrate that LCs
traveling from the epidermis to the dermis were capable of
taking up vaccine compounds in vivo.
To investigate further the transport of antigens, DLNs
were subsequently monitored for CD11cþCD207þCD103
(resident and migrating) LCs at several time points after MVA
dermal immunization (n¼ 7 mice, two independent experi-
ments). First, a significant increase in the absolute number of
LCs was observed at 24 hours after MVA injection when
compared with PBS-treated mice (Po0.05; Figure 3a). These
LCs expressed high levels of the activation marker CD86
24hours after MVA injection, as compared with the control
group (Po0.01; Figure 3b). More importantly, the percentage
of MVA-EGFPþ LCs in the DLNs was also increased in MVA-
EGFP-injected animals compared with control mice (n¼ 7
mice, two independent experiments; Po0.05; Figure 3c).
MVA-EGFPþ LCs from the DLNs were sorted by flow
cytometry at 24 hours for microscopic analyses and showed
the intracellular presence of the green antigens (Figure 3d).
These results are similar to previous observations in LCs
sorted from dermal suspensions (Figure 2d). Similarly,
high levels of activation marker CD86 were detected in
MVA-EGFPþ LCs from DLNs 24 hours after ID injection
when compared with control cells (Figure 5e).
Thus, epidermal LCs actively participate in antigen
shuttling from the dermis to the DLNs within the first 24 hours
after the dermal inoculation of a particulate vaccine.
Epidermal LCs are essential for the induction of MVA-specific
CD8 T cells but not for MVA-specific CD4 T cells or the
humoral response after ID vaccination
To investigate the role of epidermal LCs in the induction
of immune responses following the dermal administration of
MVA, we used the Langerin–diphtheria toxin receptor (DTR)
transgenic mice (Kissenpfennig et al., 2005). Figure 4a shows
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Figure 1. Morphological modifications and decrease in density of epidermal Langerhans cells (LCs) after intradermal (ID) injection of particle-based vaccines.
Epidermal sheets were immunostained with anti-CD207 (Texas Red) at different time points following ID injection of phosphate-buffered saline (PBS;
discontinued line), 6-Coumarin poly D, L-lactic acid (PLA; continued line, left panels), or MVA-EGFP (continued line, right panels). (a) LC dendrite length
in micrometers (mean±SD; n¼10–20 fields), (b) the number of primary dendrites/LC (mean±SD; n¼ 15–60 fields), or (c) the number of CD207þ cells per mm2
of epidermis (mean±SD; n¼9 mice per time point) were monitored at different time points. Mann–Whitney U-test: ***Po0.001. Representative LCs (a, b)
or epidermal sheets (c) are shown below each graph. Bar¼10 mm.
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the protocol used for conditional depletion of CD207þ cells
in the skin, based on the previous work by the group of
Malissen (Bursch et al., 2007; Ginhoux et al., 2007). As
shown in Figure 4a, a first group of mice received diphtheria
toxin (DT) 2 days before ID inoculation of MVA (condition 1),
lacking both LCs and CD207þ DDCs in the skin at the time
of vaccination. A second group of mice received DT 13 days
before ID injection, lacking only epidermal LCs at the time
of vaccination. These data were verified by skin histology
studies before our experiment and were compared with
control PBS-injected mice (Supplementary Figure S2 online).
Indeed, we confirmed the results obtained by the group of
Malissen, which stipulate that 4 days after DT treatment the
CD207þ DDCs have reconstituted the dermis, whereas it
takes 18 days for LCs to reconstitute the epidermis (Ginhoux
et al., 2007).
At 7 days post ID immunization with MVA or PBS (control
group), we measured both antigen-specific cellular and
humoral responses. First, we assessed the absolute numbers
and percentages of MVA-specific IFN-g-producing effector
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Figure 2. Migration of Langerhans cells (LCs) to the dermis and capture of modified virus Ankara (MVA)-enhanced green fluorescent protein (EGFP) after
intradermal (ID) immunization. (a) Flow cytometry analyses of epidermal or dermal cell suspensions 6 hours after phosphate-buffered saline (PBS) or MVA ID
immunization (n¼ 6 mice, four independent experiments). In the epidermis, resident LCs are CD11cþCD207þCD103. In the dermis, cells are gated on
the CD11c marker: (1) resident CD207þ dermal dendritic cells (DDCs) (CD11cþCD207þCD103þ ), (2) resident CD103þ DDCs (CD11cþCD207CD103þ ),
and (3) migrating epidermal LCs (CD11cþCD207þCD103 cells). (b) Percent control of LCs in the epidermis or dermis 6 hours after PBS or MVA ID
immunization. (c) Representative ear cryosections 6 hours after MVA-EGFP ID immunization. Bar¼ 25 mm. D, dermis; E, epidermis; HF, hair follicle.
(d) EGFPþ and EGFP LCs sorted from dermal suspensions and immunostained as indicated, 6 hours after ID immunization. Bar¼5 mm (n¼2 independent
experiments). DAPI, 40,6-diamidino-2-phenylindole.
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CD4 and CD8 T cells in auricular DLNs, using an
intracellular cytokine assay (Figure 4b and c). MVA-specific
effector CD8 T cells in auricular DLNs were severely reduced
when both epidermal LCs and CD207þ DDCs were absent at
the time of ID injection (Figure 4b, condition 1; Po0.001),
and also in mice that lacked only LCs (Figure 4b, condition 2;
Po0.001) as compared with control PBS-treated mice. In
contrast, DT treatment did not affect MVA-specific IFN-g-
producing effector CD4 T cells (Figure 4c, condition 1 or 2).
Results are shown for neutralizing antibody titers (Figure 4d)
in the serum of mice that lacked LCs only or both LCs
and CD207þ DCs at the time of MVA ID injection.
MVA-specific neutralizing antibodies remained unchanged
in all conditions.
Thus, we have demonstrated the crucial role played
in vivo by epidermal LCs for the generation of MVA-specific
CD8 T cells but not for MVA-specific CD4 T cells and
humoral responses after dermal administration of a vaccine.
Interlayer movement of LCs in human skin explants after
ID injection of particle-based compounds
LC translocation was also investigated in human skin explants
after ID injection of non-fluorescent MVA (1.5107 plaque-
forming unit (PFU)) or PBS. Similar to the experiments
conducted in the mouse model, we monitored LC morphol-
ogy (as defined by dendrite length) and epidermal LC numbers
with microscopic analyses, using anti-human CD1a in
50 randomly chosen epidermal sheet layers (Figure 5b).
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We observed a significant decrease in LC-associated den-
drite length on epidermal sheets 4 hours after MVA ID injec-
tion when compared with an ID injection of PBS (Po0.001;
Figure 5a).
As depicted in Figure 5c, we found a significant
accumulation of LCs (high expression of CD1a) in the dermis
4 hours following FITC nanoparticles ID inoculation when
compared with PBS-injected skin controls (Po0.001). Inter-
estingly, after the ID injection of FITC nanoparticles,
numerous CD1aþ LCs were distributed outside the base
of the epidermal layer in contrast to PBS-injected skin
(Figure 5d). These results further support the relevance
of interlayer LCs movement after ID immunization of
particle-based compounds in the human skin.
DISCUSSION
Following the dermal inoculation of vaccine compounds,
epidermal LCs rapidly translocate into the dermis and
vigorously participate in CD8 but not CD4 and humoral
anti-MVA immune responses. Morphological changes,
trans-layer movement, uptake of antigens, and migration of
LCs from the skin to the DLN were the main features of these
early events.
A report by Pearton et al. (2010) also demonstrates
morphological changes of LCs in human skin explants after
the dermal injection of virus-like particles. We have,
however, noted differences in the kinetics of LC modifica-
tions between the two studies. In the work of Pearton et al.,
there is a marked lack of monitoring of changes in both the
morphology and number of LCs at time points earlier than
24 hours following ID injection. Indeed, we found that
the presence of LCs in the dermis was transient (only a few
hours). It has been shown that under inflammatory condi-
tions, epidermal LCs derived from blood-borne monocytes
rapidly replenished the epidermis (Merad et al., 2002). The
expression of CCR6 on the surface of these blood-borne
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monocytes then allows them to differentiate into LCs in the
epidermis in response to the expression of the chemokine
MIP3a, which is secreted by resident keratinocytes (Ginhoux
et al., 2006). This could explain why, in our study, LC
numbers in the epidermis were already replenished 24 hours
after ID injection. The different molecular mechanisms
featuring LC reconstitution in the skin after an ID inoculation
need to be further studied.
In addition to the previous work of Pearton et al. (2010), we
provide the first evidence for the involvement of epidermal LCs
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in particulate-vaccine shuttling from the dermis to draining
lymphoid tissues. We and others have shown that in addition to
skin-resident APCs, other inflammatory cells are recruited to
the site of injection after the ID administration of a vaccine;
e.g., neutrophils in the case of the Bacillus Calmette-Gue´rin
(Abadie et al., 2005) or blood-borne monocytes in the MVA
model (Abadie et al., 2009). These cell subsets also participate
in antigen transport from the skin to the DLN.
Allan et al. (2003, 2006) have suggested that in the case of
an Herpes simplex virus skin infection, LCs do not directly
prime T cells in the DLNs but function as ‘‘antigen carriers’’
for CD8aþ DLN-resident DCs. Regardless of the scenario
involved, i.e., direct T-cell priming by skin migrating LCs or
indirect cross-priming through CD8aþ DLN-resident DCs
that obtain antigens from ‘‘cargo LCs’’, our results show that
epidermal LCs are indispensable for the induction of CD8
T-cell responses. However, LCs were expendable for the
generation of MVA-specific CD4 T cells, as well as specific
neutralizing antibodies. Our findings are consistent with
recent data in the literature, which suggest that humoral and
cellular responses are regulated by different subsets of skin
and DLN DCs with distinct intrinsic properties (Ueno et al.,
2010a). In addition, several in vitro studies have shown that
CD34þ -derived LCs and human skin LCs were more potent
at priming IFN-g-secreting CD8þ T cells than DDCs
(Caux et al., 1997; Ratzinger et al., 2004; Klechevsky et al.,
2008). Moreover, Kissenpfennig et al. (2005) have demon-
strated, in the Langerin–DTR murine model, that after topical
immunization (TRITC-painting), epidermal LCs were prefer-
entially localized in the inner paracortex of the DLN, in the
T-cell zone, in close proximity to the CD8aþ -resident DCs.
LCs are also capable of inducing cytotoxic cellular immune
responses for protection against tumors in mice (Stoitzner
et al., 2008) and also in humans (Fay et al., 2006). The fact
that transcutaneous vaccination targeting LCs surrounding
hair follicles (Vogt et al., 2006) induces preferentially
CD8-mediated cellular immunity (Combadiere et al., 2010)
confirms this unique feature of LCs.
Langerin–DTR mouse model allows to explore the role
of CD207þ skin DCs (DDCs and/or LCs) in the initiation of
immune responses to different types of vaccine administra-
tions or infections (Romani et al., 2010a). Recent studies have
highlighted the importance of CD207þ DCs for the induction
of specific CD8 T-cell responses after an ID plasmid DNA
immunization (Elnekave et al., 2010) or after an ID injection
of a lentiviral vector (Furmanov et al., 2010), as well as in the
context of gene gun vaccination (Stoecklinger et al., 2011).
LCs are major factors of the immunity against skin viruses
such as Herpes simplex virus and Varicella, which function
by transporting the virus to the DLN (Bedoui et al., 2009;
Cunningham et al., 2010). In addition, both LCs and CD207þ
DDCs would be involved in contact hypersensitivity depend-
ing on the hapten dose (Kaplan et al., 2005; Bennett et al.,
2007; Honda et al., 2010; Noordegraaf et al., 2010).
Eventually, Nudel et al. (2011) proved the crucial role of
LCs in the induction of CD8 T cells after an oral mucosal
immunization. Indeed, the nature of the vaccine preparation
or of the pathogen, as well as the antigen dose and the route
of administration, are important parameters that could
influence the differential involvement of LCs or CD207þ
DCs for the induction of immune responses. LCs are
undeniably of major importance for the induction of Th1
immune responses; i.e., to fight Borrelia burdorferi in the
Lyme disease (Vesely et al., 2009), or for the generation of
alloreactive cytotoxic T lymphocytes in the skin after bone
marrow stem cell transplantation (graft-versus-host disease;
Merad et al., 2004).
Contrary to transcutaneous or topical application of
vaccine compounds, the ID route does not preferentially
target LCs, but instead target resident DDCs, which are
more involved in the induction of T-follicular helper (Tfh)
cells in vitro. This specific T-cell subset contributes to the
switching and proliferation of B cells within the germinal
centers, leading to the production of large amounts of
different subtypes of immunoglobulins (Klechevsky et al.,
2008). The ID route thus allows the mobilization of both arms
of the immune response by harnessing the unique plasticity of
cutaneous APCs distributed among the different skin com-
partments. Our work is of major importance for the under-
standing of cellular mechanisms related to an ID inoculation.
It provides new evidence for the role of LCs in the induction
of immune responses to particle-based vaccines injected into
the skin. Moreover, it paves the way for other studies that will
aim at fully understanding the primary immune events
triggered by ID administered compounds.
MATERIALS AND METHODS
Mice
Female Balb/c mice (6- to 8-week old) were purchased from Charles
River Laboratories (L’Arbresle, Orle´ans, France) and Langerin–DTR
mice (Kissenpfennig et al., 2005) from the Transgenesis, Archiving
and Animal Models (CNRS laboratory, Orle´ans, France). Langer-
in–DTR mice received 1 mg of diphtheria toxin (Sigma-Aldrich, Saint-
Quentin Fallavier, France) intraperitoneally 2 or 13 days before ID
vaccination. All animals were housed at the specific pathogen-free
animal facility of the Pitie´-Salpe´trie`re hospital (Paris, France). All
experiments complied with the local animal experimentation and
ethics committee guidelines.
Human skin explants
Fresh skin samples were obtained from healthy volunteers under-
going plastic surgery: mandibular region of the face or retroareolar
region of the breast (Charite´ Hospital, Berlin, Germany). All skin
explants were taken after informed consent obtained by the
Institutional Ethics Committee of the Charite´ Hospital (Berlin,
Germany) according to the ethical rules stated in the Declaration
of Helsinki Principles.
A few hours after surgical excision, intact skin samples were injected
ID (Mantoux injection technique) with 6 105 FluoSpheres (40nm
yellow-green FITC nanoparticles; Molecular Probes, Life Technologies,
Carlsbad, CA), 1.5 107 PFUMVA, or PBS, using U-100 insulin needles
(29G 1/2000.33 12mm; Terumo, Interleuvenlaan, Belgium).
Mice immunization
Mice received a single ID injection at the back of the ear as
previously described (Abadie et al., 2009). A volume of 30 ml of
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vaccine was used; i.e., 3.0 1010 6-Coumarin PLA (Lamalle-Bernard
et al., 2006; Primard et al., 2010) or 1.5 107 PFU MVA-EGFP
(fluorescent virus particles) or MVA (non-fluorescent). Control
animals were injected ID with PBS.
MVA-EGFP neutralization assay
Blood was collected in dry Eppendorf tubes before ID immunization
(pre-immune samples) and at 21 days post priming. Centrifuged sera
were collected and stored at 80 1C.
Neutralizing antibody titers were determined using a neutraliza-
tion assay as previously described (Abadie et al., 2009). The
percentage of neutralization was calculated as follows: (1[percen-
tage of GFP-expressing cells in treated samples/percentage of
GFP-expressing cells in untreated controls]) 100.
Preparation of murine cell suspensions
DLNs were treated for 30minutes at 37 1C with collagenase IV
(Sigma-Aldrich), 400Uml1 in RPMI 1640 medium (Invitrogen
Europe, Paisley, UK), pressed through a 70-mm nylon mesh
(cell strainer, BD Falcon, Franklin Lakes, NJ), and washed with
PBS supplemented with fetal calf serum (FCS).
For skin cell preparation, epidermis was separated from the
dermis as follows: the dorsal halves of the ears were incubated,
epidermal side down, for 30minutes at 37 1C in ammonium
thiocyanate phosphate buffer (0.5 M). The dermal layer was
mechanically separated by gently peeling off the epidermis with
tweezers. Small pieces of dermis and epidermis were pooled
separately in 2.5U Dispase-II (Sigma) and dissociated overnight
with gentle shaking at 4 1C. Digested tissues were pressed through a
70-mm nylon mesh (cell strainer) and then filtered (Miltenyi, Auburn,
CA) in order to remove most aggregates.
Flow cytometry
Cell suspensions were stained for surface markers (20minutes at 4 1C
in PBS 1 , 2% FCS) with biotinylated anti-mouse CD103 (Integrin
a-IEL chain; clone M290) and anti-mouse CD11c-APC (clone HL3).
Streptavidin-PerCp was used for detection. All antibodies were
purchased from BD Biosciences (Franklin Lakes, NJ). Anti-mouse
CD86-FITC (clone GL1) or anti-mouse CD86-PE-Cy7 allowed the
detection of activated cells. Cells were sequentially fixed with 4%
paraformaldehyde for 20minutes at 4 1C, rinsed, and permeabilized
with 2% FCS—0.1% saponin (Sigma)—PBS 1 . Intracellular
staining was performed using PE-conjugated anti-mouse CD207/
Langerin (clone eBioL31). Fluorescence was analyzed on a total of
2 105 cells of each population per sample with a LSRII flow
cytometer or a FACSCalibur and analyzed using the FlowJo software
(Becton Dickinson, San Jose, CA).
Intracellular cytokine assay
DLN cells were cultured for 16 hours at 37 1C with 0.1 PFU MVA per
cell, RPMI (negative control), or 2.5 mg concanavalin A (positive
control). This was incubated for 4 hours at 37 1C with 5 mgml1
brefeldin A to block cytokine secretion. Cellular suspensions were
washed and surface stained for 20minutes at 4 1C with anti-mouse
CD8a (Ly-2)–PercP-Cy5.5 (clone 53-6.7) and anti-mouse CD4-PE
(BD Biosciences), respectively, in PBS-5% FCS. Cells were fixed with
4% paraformaldehyde before intracellular staining with a mix of
anti-mouse IL2-FITC and anti-mouse IFN-g-APC (20minutes at 4 1C).
Fluorescence was monitored on a minimum of 50,000 CD8þ /CD4þ
cells with a FACSCalibur (BD Biosciences) and analyzed using
the FlowJo software.
Immunofluorescence
Mice ear skin (ID injection sites) or auricular DLNs were removed
after ID injection at indicated time points. Cell suspensions
(epidermis, dermis, or auricular DLN) were surface stained using
anti-mouse CD103-biotin (streptavidin-PerCp-Cy5.5) and anti-
mouse CD11c-APC. CD11cþCD103 cells with or without MVA-
EGFP were sorted using a FACSVantage cell sorter (Becton
Diskinson) and coated onto Poly-L-lysine (Sigma-Aldrich) coverslips
in RPMI with 30% FCS. Cell staining was performed directly on
the coverslips with slight shaking, using purified biotinylated rat
anti-CD207 (Euromedex, Soufellweyersheim, France).
Murine skin was removed at indicated time points, embedded
in optimum cutting temperature medium (Tissue-Tek, Sakura
Finetek, Alphen aan den Rijn, The Netherlands), frozen, and
sequentially cryosectioned (5mm) with a Microm HM550 cryostat
(Thermo Scientific, Courtaboeuf, France). Immunostainings were
performed as described previously (Mahe et al., 2009) using
biotinylated rabbit-anti-MVA (AbCys SA), Streptavidin Alexa 488
(Molecular Probes), purified biotinylated rat anti-CD207 (Eurome-
dex), and chicken anti-rat IgG-Alexa Fluor 594 (Invitrogen Europe).
Slides were coverslipped with Vectashield mounting medium
containing 40,6-diamidino-2-phenylindole (Vector Laboratories,
Abscys sa, Paris, France). The dermal layer of mouse ears was
mechanically separated from the epidermis as described above. After
fixation in 1% paraformaldehyde (20minutes at 4 1C), epidermal
sheets were incubated by gently shaking with, in sequence, a
biotinylated anti-mCD207 mAb (Clone 929F3-01; Euromedex) and
Texas Red-conjugated streptavidin (Zymco, Invitrogen, Carlslab,
CA). They were mounted for microscopy using the Fluoromount-G
medium (Southern-Biotechnology Associates, Birmingham, UK).
Human skin explants were incubated at 37 1C in a Petri dish with
DMEM-10% FCS for 4 hours after ID injection. Human skin samples
were frozen and cryosectioned as described for mouse skin. Sections
were immunostained as described previously (Vogt et al., 2006),
using, in sequence, mouse anti-hCD1a (Dako, Glostrup, Denmark)
and a secondary anti-mouse Alexa-594 antibody (Molecular Probes)
in PBS 1 containing 1% BSA. Slides were coverslipped with
Fluoromount-G supplemented with 40,6-diamidino-2-phenylindole.
Human epidermal sheets were prepared as follows: skin tissues
were digested overnight at 4 1C as described previously (Kitano and
Okada, 1983). Epidermal sheets were separated and fixed in 1%
paraformaldehyde in PBS 1 for 20minutes at 4 1C. Immunostain-
ing was performed using, in sequence, mouse anti-human CD1a
antibodies (Dako; Glostrup, Denmark, Biotest, Dreieich, Germany)
and secondary anti-mouse-FITC antibodies diluted in human serum
(Vector laboratories, Burlingame, CA), and mounted for microscopy
using Fluoromount-G medium (Southern-Biotechnology Associates).
Microscopy analyses
All tissues were analyzed with a fluorescence microscope (BX51;
Olympus, Rungis, France) or a BX60F3 microscope (Olympus,
Hamburg, Germany) equipped with an image processing and
analysis system (Qimaging; Media Cybernetics, Bethesda, MD).
All measurements were recorded using the software ImageJ
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(NIH, Bethesda, MD). Quantitative parameters for LCs morphology
and density in skin tissues have been chosen according to the
literature ((Pearton et al., 2010, skin LCs, or (Gervaz et al., 1995,
anal mucosa LCs)).
Statistical analyses
Data are presented as the mean±standard deviation. Statistical
analyses were performed with the Graphpad software. P-values of
o0.05 were considered statistically significant.
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